Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Equities research analysts at Piper Jaffray Companies raised their FY2018 EPS estimates for shares of Endo International in a note issued to investors on Thursday, November 8th. Piper Jaffray Companies analyst D. Amsellem now forecasts that the company will post earnings of $2.73 per share for the year, up from their previous estimate of $2.55. Piper Jaffray Companies also issued estimates for Endo International’s Q1 2019 earnings at $0.51 EPS and Q2 2019 earnings at $0.63 EPS.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Thursday, November 8th. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.12. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The firm had revenue of $745.00 million during the quarter, compared to analysts’ expectations of $694.93 million. During the same period last year, the business posted $0.91 earnings per share. The company’s revenue for the quarter was down 5.3% compared to the same quarter last year.
ENDP has been the subject of several other reports. Deutsche Bank set a $11.00 price objective on Endo International and gave the stock a “buy” rating in a research note on Wednesday, July 18th. ValuEngine upgraded Endo International from a “strong sell” rating to a “sell” rating in a research note on Wednesday, July 25th. BidaskClub cut Endo International from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 8th. Morgan Stanley lifted their price target on Endo International from $7.00 to $17.00 and gave the company an “equal weight” rating in a research report on Friday, August 17th. Finally, Zacks Investment Research cut Endo International from a “buy” rating to a “hold” rating in a research report on Tuesday, September 18th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Endo International presently has a consensus rating of “Hold” and a consensus target price of $15.44.
Shares of NASDAQ:ENDP opened at $13.49 on Friday. Endo International has a 52-week low of $5.27 and a 52-week high of $18.50. The stock has a market capitalization of $3.59 billion, a PE ratio of 3.51, a PEG ratio of 1.54 and a beta of 0.65.
In other Endo International news, Director Roger H. Kimmel sold 26,074 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total value of $414,576.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.80% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Xact Kapitalforvaltning AB boosted its stake in shares of Endo International by 44.5% in the first quarter. Xact Kapitalforvaltning AB now owns 29,215 shares of the company’s stock worth $174,000 after acquiring an additional 9,000 shares during the last quarter. Comerica Bank boosted its stake in shares of Endo International by 35.6% in the second quarter. Comerica Bank now owns 214,561 shares of the company’s stock worth $2,324,000 after acquiring an additional 56,354 shares during the last quarter. New York State Teachers Retirement System boosted its stake in shares of Endo International by 27.0% in the second quarter. New York State Teachers Retirement System now owns 356,957 shares of the company’s stock worth $3,366,000 after acquiring an additional 75,844 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of Endo International by 9.6% in the second quarter. Alps Advisors Inc. now owns 501,708 shares of the company’s stock worth $4,731,000 after acquiring an additional 43,791 shares during the last quarter. Finally, Price Capital Management Inc. acquired a new stake in shares of Endo International in the second quarter worth approximately $720,000. 98.43% of the stock is currently owned by institutional investors.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Further Reading: What are the Benefits of Index Funds?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.